炎症性肠病(IBD)包括主要影响胃肠道的全身性炎症,包括克罗恩病和溃疡性结肠炎。本研究旨在分析右旋糖酐硫酸钠(DSS)诱导的犬IBD模型的临床症状和发病机制,并从发病机制的角度评价人参皂苷的修复作用。我们建立了DSS诱导的犬IBD模型并研究了其病理机制。此外,我们通过评估犬炎症性肠病活动指数(CIBDAI)来检查人参皂苷的治疗效果,C反应蛋白(CRP)水平,结肠组织形态学,蛋白质表达,和粘膜细菌群落分析。我们的发现揭示了人参皂苷提取物中人参皂苷的总含量为22.7%。动物实验表明,IBD犬的精神状态下降,CIBDAI和CRP水平显著升高,结肠上皮组织结构破坏,粘蛋白表达减少,紧密连接,和信徒的连接处,以及结肠粘膜细菌群落的多样性减少。此外,相关性分析突出显示了总共38个与生理指标相关的细菌菌株。重要的是,人参皂苷治疗可以改善这些症状并逆转一些细菌群落的相对丰度。总之,结肠粘液层性质的改变或MUC2,其核心成分的减少,在患有IBD的狗中,会导致粘液层的细菌渗透并随后与肠上皮细胞接触,导致炎症。值得注意的是,人参皂苷干预显示了积极影响细菌相对丰度和影响结肠粘液层性质的能力,从而为IBD的管理和恢复提供了有希望的前景。
Inflammatory bowel disease (IBD) comprises systemic inflammatory conditions primarily affecting the gastrointestinal tract, including Crohn\'s disease and ulcerative colitis. This research aims to analyze the clinical symptoms and pathogenesis of a Dextran sodium sulfate (DSS)-induced canine IBD model and evaluate the restorative effect of ginsenoside from a pathogenesis perspective. We established the DSS-induced canine IBD model and studied the pathological mechanisms. Additionally, we examined the therapeutic effect of ginsenosides by assessing the Canine Inflammatory Bowel Disease Activity Index (CIBDAI), C-reactive protein (CRP) levels, colonic tissue morphology, protein expression, and mucosal bacterial community analysis. Our findings revealed a total ginsenoside content of 22.7% in the ginsenoside extract. Animal experiments demonstrated that dogs with IBD exhibited decreased mental state, significantly increased CIBDAI and CRP levels, disrupted colonic epithelial tissue structure, decreased expression of mucin, tight junctions, and adherens junctions, as well as reduced diversity of the colonic mucosal bacterial community. Furthermore, correlation analysis highlighted a total of 38 bacterial strains correlated with physiological indices. Significantly, ginsenoside treatment could improve these symptoms and reverse the relative abundance of some bacterial communities. In conclusion, alterations in the properties of the colonic mucus layer or the reduction in MUC2, its core component, in dogs with IBD can lead to bacterial penetration of the mucus layer and subsequent contact with intestinal epithelial cells, resulting in inflammation. Remarkably, ginsenoside intervention showcased the capacity to positively influence the relative abundance of bacteria and impact the colonic mucus layer properties, thereby offering promising prospects for IBD management and recovery.